Annabel Samimy
Stock Analyst at Stifel
(4.60)
# 373
Out of 4,479 analysts
41
Total ratings
52.63%
Success rate
45.98%
Average return
Main Sectors:
Top Industries:
20 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CALT Calliditas Therapeutics AB (publ) | Downgrades: Hold | $55 → $40 | $38.75 | +3.23% | 2 | May 28, 2024 | |
| PHAT Phathom Pharmaceuticals | Initiates: Buy | $24 | $10.25 | +134.15% | 1 | May 3, 2024 | |
| RGNX REGENXBIO | Maintains: Buy | $40 | $10.75 | +272.09% | 2 | Apr 12, 2024 | |
| VKTX Viking Therapeutics | Reiterates: Buy | $80 | $51.54 | +55.22% | 6 | Mar 15, 2024 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $225 → $230 | $105.09 | +118.86% | 3 | Mar 15, 2024 | |
| EOLS Evolus | Reiterates: Buy | $23 → $25 | $10.66 | +134.52% | 1 | Mar 8, 2024 | |
| IVA Inventiva | Maintains: Buy | $27 → $25 | $2.85 | +777.19% | 2 | Feb 16, 2024 | |
| OCS Oculis Holding AG | Initiates: Buy | $35 | $11.70 | +199.15% | 1 | Oct 5, 2023 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $60 → $65 | $34.98 | +85.82% | 3 | Aug 29, 2023 | |
| CARA Cara Therapeutics | Reiterates: Buy | $28 | $0.28 | +9,975.57% | 2 | Jun 27, 2023 | |
| FGEN FibroGen | Downgrades: Hold | $28 → $11 | $0.74 | +1,380.48% | 3 | Jun 26, 2023 | |
| MLYS Mineralys Therapeutics | Initiates: Buy | $45 | $12.09 | +272.21% | 1 | Mar 7, 2023 | |
| CLSD Clearside Biomedical | Upgrades: Buy | $8 | $1.23 | +550.41% | 1 | Nov 10, 2022 | |
| EVFM Evofem Biosciences | Downgrades: Hold | $375 → $63 | $0.01 | +568,081.82% | 2 | Oct 13, 2022 | |
| RANI Rani Therapeutics Holdings | Initiates: Buy | n/a | $3.87 | - | 1 | Aug 24, 2021 | |
| RDUS Radius Health | Initiates: Hold | n/a | $14.67 | - | 1 | Apr 24, 2020 | |
| TXMD TherapeuticsMD | Maintains: Buy | n/a | $1.66 | - | 2 | Apr 16, 2020 | |
| SUPN Supernus Pharmaceuticals | Maintains: Hold | n/a | $25.77 | - | 4 | Apr 16, 2020 | |
| RVNC Revance Therapeutics | Maintains: Buy | n/a | $2.42 | - | 1 | Apr 16, 2020 | |
| DRRX DURECT | Downgrades: Hold | n/a | $1.36 | - | 2 | Oct 20, 2017 |
Calliditas Therapeutics AB (publ)
May 28, 2024
Downgrades: Hold
Price Target: $55 → $40
Current: $38.75
Upside: +3.23%
Phathom Pharmaceuticals
May 3, 2024
Initiates: Buy
Price Target: $24
Current: $10.25
Upside: +134.15%
REGENXBIO
Apr 12, 2024
Maintains: Buy
Price Target: $40
Current: $10.75
Upside: +272.09%
Viking Therapeutics
Mar 15, 2024
Reiterates: Buy
Price Target: $80
Current: $51.54
Upside: +55.22%
Jazz Pharmaceuticals
Mar 15, 2024
Maintains: Buy
Price Target: $225 → $230
Current: $105.09
Upside: +118.86%
Evolus
Mar 8, 2024
Reiterates: Buy
Price Target: $23 → $25
Current: $10.66
Upside: +134.52%
Inventiva
Feb 16, 2024
Maintains: Buy
Price Target: $27 → $25
Current: $2.85
Upside: +777.19%
Oculis Holding AG
Oct 5, 2023
Initiates: Buy
Price Target: $35
Current: $11.70
Upside: +199.15%
Apellis Pharmaceuticals
Aug 29, 2023
Maintains: Buy
Price Target: $60 → $65
Current: $34.98
Upside: +85.82%
Cara Therapeutics
Jun 27, 2023
Reiterates: Buy
Price Target: $28
Current: $0.28
Upside: +9,975.57%
FibroGen
Jun 26, 2023
Downgrades: Hold
Price Target: $28 → $11
Current: $0.74
Upside: +1,380.48%
Mineralys Therapeutics
Mar 7, 2023
Initiates: Buy
Price Target: $45
Current: $12.09
Upside: +272.21%
Clearside Biomedical
Nov 10, 2022
Upgrades: Buy
Price Target: $8
Current: $1.23
Upside: +550.41%
Evofem Biosciences
Oct 13, 2022
Downgrades: Hold
Price Target: $375 → $63
Current: $0.01
Upside: +568,081.82%
Rani Therapeutics Holdings
Aug 24, 2021
Initiates: Buy
Price Target: n/a
Current: $3.87
Upside: -
Radius Health
Apr 24, 2020
Initiates: Hold
Price Target: n/a
Current: $14.67
Upside: -
TherapeuticsMD
Apr 16, 2020
Maintains: Buy
Price Target: n/a
Current: $1.66
Upside: -
Supernus Pharmaceuticals
Apr 16, 2020
Maintains: Hold
Price Target: n/a
Current: $25.77
Upside: -
Revance Therapeutics
Apr 16, 2020
Maintains: Buy
Price Target: n/a
Current: $2.42
Upside: -
DURECT
Oct 20, 2017
Downgrades: Hold
Price Target: n/a
Current: $1.36
Upside: -